Engineering a production platform for the potent antipseudomonal antibiotic mureidomycin A by reprogramming the pacidamycin biosynthetic gene cluster.
9 affiliations
- 1Department of Pharmaceutical Biology, Eberhard Karls University Tübingen, Tübingen, 72076, Germany.
- 2German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, 72076, Germany.
- 3Department of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, Eberhard Karls University Tübingen, Tübingen, 72076, Germany.
- 4Institute for Bioinformatics and Medical Informatics, Eberhard Karls University Tübingen, Tübingen, 72076, Germany.
- 5Institute for Pharmaceutical Microbiology, University of Bonn, University Hospital Bonn, Bonn, 53127, Germany.
- 6German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, 53113, Germany.
- 7School of Chemistry, Institute of Engineering, University of St Andrews, St Andrews, KY16 9ST, UK.
- 8Department of Pharmaceutical Biology, Eberhard Karls University Tübingen, Tübingen, 72076, Germany. [email protected].
- 9German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, 72076, Germany. [email protected].
Abstract
Background
Uridyl peptide antibiotics display potent activity against Pseudomonas aeruginosa, a pathogen causing severe nosocomial infections. The four subclasses-mureidomycins, pacidamycins, napsamycins, and sansanmycins-inhibit the underexplored bacterial target phospho-MurNAc-pentapeptide translocase (MraY). Structurally, these compounds contain a 3'-deoxyuridine linked to a central diaminobutyric acid. The latter is situated within a pseudo tetra- or pentapeptide moiety, assembled by a non-ribosomal peptide synthetase machinery. The subclasses are distinguished by variations in the incorporated amino acids. Native producer strains typically synthesize numerous different uridyl peptide antibiotics in low yields. Since the pacidamycin gene cluster displays higher overall yields compared to the napsamycin cluster in identical expression systems, we aimed to reprogram it into a selective production platform for the highly bioactive mureidomycin A. This approach is intended to streamline isolation processes and support hit-to-lead optimization.Results
Streptomyces albus J1074 was identified as the most promising host for heterologous expression of the pacidamycin gene cluster. Subsequently, media screening and precursor feeding were conducted, and regulators of closely related gene clusters were introduced into the heterologous host. The overexpression of the NpsM regulator of the napsamycin gene cluster increased production significantly. Next, the pacidamycin gene cluster was engineered to produce the more potent mureidomycins. Variable positions of the peptide moiety were individually targeted by domain or module swaps of the non-ribosomal peptide synthetase machinery. More specifically, these were replaced by homologs of the napsamycin gene cluster, resulting in strains mainly producing sansanmycin A or mureidomycin A. Promoter engineering enhanced mureidomycin A production in the final strain, correlating with increased transcription levels in RNA sequencing experiments on an intermediate strain harboring the same promoters.Conclusions
Hybrid uridyl peptide antibiotic gene clusters were constructed by genetically engineering the pacidamycin cluster, demonstrating the versatility of these clusters. While the native pacidamycin cluster only produced pacidamycin D and S, the final strain yields the more bioactive mureidomycin A and Met-pacidamycin 5. Additionally, sansanmycin A (syn. Met-pacidamycin 4) can be isolated from an intermediate construct of this study. This expands the access to different analogs and highlights further engineering potential, which will facilitate the future development of these promising antibiotics.
Related
- Engineering the FK228 biosynthetic gene clusters for high-yield production
- Toxin-mediated tRNATrp depletion drives Trp-codon-dependent reprogramming in Mycobacterium tuberculosis while selectively enriching the PDIM biosynthetic machinery
- Engineering clinically actionable nanomedicine for cancer immunometabolic ecosystem reprogramming
- Tertiary structure of a Nif11-like leader peptide mediates protein-protein interactions with a RiPP biosynthetic enzyme
- An automated operon refactoring workflow for heterologous expression of non-ribosomal peptide biosynthetic gene clusters
BibTeX
@article{koutsandrea2026engineering,
title = {{Engineering a production platform for the potent antipseudomonal antibiotic mureidomycin A by reprogramming the pacidamycin biosynthetic gene cluster.}},
author = {Panagiota-Hanna Koutsandrea and Richard Sonnengrün and Nils Hauck and Andreas Kulik and Theresa Harbig and Jan-Martin Daniel and Kay Katja Nieselt and Rebecca Jane Miriam Goss and Tanja Schneider and Silja Mordhorst and Harald Gross and Bertolt Gust},
journal = {Microbial cell factories},
year = {2026},
month = oct,
doi = {10.1186/s12934-026-03166-9},
url = {https://europepmc.org/article/MED/42963568},
note = {CC BY},
}
RIS
TY - JOUR
TI - Engineering a production platform for the potent antipseudomonal antibiotic mureidomycin A by reprogramming the pacidamycin biosynthetic gene cluster.
AU - Panagiota-Hanna Koutsandrea
AU - Richard Sonnengrün
AU - Nils Hauck
AU - Andreas Kulik
AU - Theresa Harbig
AU - Jan-Martin Daniel
AU - Kay Katja Nieselt
AU - Rebecca Jane Miriam Goss
AU - Tanja Schneider
AU - Silja Mordhorst
AU - Harald Gross
AU - Bertolt Gust
PY - 2026
DA - 2026/10/30
JO - Microbial cell factories
DO - 10.1186/s12934-026-03166-9
UR - https://europepmc.org/article/MED/42963568
AB - Background Uridyl peptide antibiotics display potent activity against Pseudomonas aeruginosa, a pathogen causing severe nosocomial infections. The four subclasses-mureidomycins, pacidamycins, napsamycins, and sansanmycins-inhibit the underexplored bacterial target phospho-MurNAc-pentapeptide translocase (MraY). Structurally, these compounds contain a 3'-deoxyuridine linked to a central diaminobutyric acid. The latter is situated within a pseudo tetra- or pentapeptide moiety, assembled by a non-ribosomal peptide synthetase machinery. The subclasses are distinguished by variations in the incorporated amino acids. Native producer strains typically synthesize numerous different uridyl peptide antibiotics in low yields. Since the pacidamycin gene cluster displays higher overall yields compared to the napsamycin cluster in identical expression systems, we aimed to reprogram it into a selective production platform for the highly bioactive mureidomycin A. This approach is intended to streamline isolation processes and support hit-to-lead optimization.Results Streptomyces albus J1074 was identified as the most promising host for heterologous expression of the pacidamycin gene cluster. Subsequently, media screening and precursor feeding were conducted, and regulators of closely related gene clusters were introduced into the heterologous host. The overexpression of the NpsM regulator of the napsamycin gene cluster increased production significantly. Next, the pacidamycin gene cluster was engineered to produce the more potent mureidomycins. Variable positions of the peptide moiety were individually targeted by domain or module swaps of the non-ribosomal peptide synthetase machinery. More specifically, these were replaced by homologs of the napsamycin gene cluster, resulting in strains mainly producing sansanmycin A or mureidomycin A. Promoter engineering enhanced mureidomycin A production in the final strain, correlating with increased transcription levels in RNA sequencing experiments on an intermediate strain harboring the same promoters.Conclusions Hybrid uridyl peptide antibiotic gene clusters were constructed by genetically engineering the pacidamycin cluster, demonstrating the versatility of these clusters. While the native pacidamycin cluster only produced pacidamycin D and S, the final strain yields the more bioactive mureidomycin A and Met-pacidamycin 5. Additionally, sansanmycin A (syn. Met-pacidamycin 4) can be isolated from an intermediate construct of this study. This expands the access to different analogs and highlights further engineering potential, which will facilitate the future development of these promising antibiotics.
SN - 1475-2859
ER -